--- title: "Aquestive Therapeutics (AQST) news: class action and offering" url: "https://aibio.space/companies/aquestive-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "AQST class action and offering news: Aquestive faces securities class action and derivative suit over Anaphylm NDA statements. Aquestive Therapeutics, Inc." --- AQST Aquestive Therapeutics, Inc. NASDAQ · United States # Aquestive Therapeutics (AQST) news AQST class action and offering news Legal · 2026-09-17 ## [Aquestive faces securities class action and derivative suit over Anaphylm NDA statements](https://aibio.space/news/aquestive-faces-securities-class-action-derivative-suit-anaphylm-nda/) Modica v. Aquestive names the company and chief executive Daniel Barber in New Jersey federal court. A derivative suit, Wilson v. Brown, is stayed behind it. ## Latest Aquestive Therapeutics news 1. 2026-05-12 Debt Financing [Aquestive enters $150 million debt facility with Oaktree](https://aibio.space/news/aquestive-enters-150-million-debt-facility-oaktree/) The facility refinances Aquestive's existing debt. It starts with $55.0 million at signing and adds tranches tied to FDA approval and sales milestones. 2. 2025-08-14 Financings [Aquestive Therapeutics prices $85,000,000 stock offering at $4.00 per share](https://aibio.space/news/aquestive-therapeutics-prices-85-000-000-stock-offering-4-00-share/) Aquestive sold 21,250,000 shares at $4.00 through Leerink Partners, Cantor and Oppenheimer, a day after agreeing to a conditional $75 million revenue-interest deal with an affiliate of RTW Investments. Anaphylm's approval is a condition of that deal. ## Aquestive Therapeutics at a glance - **Ticker**: AQST - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $98.5 million ### Related companies - [Rhythm Pharmaceuticals](https://aibio.space/companies/rhythm-pharmaceuticals/) NASDAQ: RYTM - [Citius Oncology](https://aibio.space/companies/citius-oncology/) NASDAQ: CTOR - [Aclaris Therapeutics](https://aibio.space/companies/aclaris-therapeutics/) NASDAQ: ACRS - [Praxis Precision Medicines](https://aibio.space/companies/praxis-precision-medicines/) NASDAQ: PRAX - [Cumberland Pharmaceuticals](https://aibio.space/companies/cumberland-pharmaceuticals/) NASDAQ: CPIX - [RegeneRx Biopharmaceuticals](https://aibio.space/companies/regenerx-biopharmaceuticals/) OTC: RGRX - [NRX Pharmaceuticals](https://aibio.space/companies/nrx-pharmaceuticals/) NASDAQ: NRXP - [MapLight Therapeutics](https://aibio.space/companies/maplight-therapeutics/) NASDAQ: MPLT ### Also on NASDAQ - [Arbutus Biopharma](https://aibio.space/companies/arbutus-biopharma/) ABUS - [Zentalis Pharmaceuticals](https://aibio.space/companies/zentalis-pharmaceuticals/) ZNTL - [PepGen](https://aibio.space/companies/pepgen/) PEPG - [Rocket Pharmaceuticals](https://aibio.space/companies/rocket-pharmaceuticals/) RCKT - [ALX Oncology Holdings](https://aibio.space/companies/alx-oncology/) ALXO - [Scinai Immunotherapeutics](https://aibio.space/companies/scinai-immunotherapeutics/) SCNI ## What Aquestive Therapeutics does Aquestive Therapeutics is a pharmaceutical company developing medicines that deliver complex molecules through alternatives to invasive and inconvenient standard of care therapies. Its late-stage product candidate, Anaphylm (dibutepinephrine), is a sublingual film for severe allergic reactions, including anaphylaxis, which the company describes as the first and only non-device based, orally delivered epinephrine prodrug in development. The FDA issued a complete response letter (CRL) on January 30, 2026, focused on administration and labeling guidance, and Aquestive plans a new human factors validation study and a resubmission of the NDA. Its AdrenaVerse platform contains a library of over twenty epinephrine prodrug product candidates, including AQST-108, an epinephrine topical gel. Its PharmFilm oral film technology has been used to ship more than two billion doses to patients worldwide. Aquestive also has four licensed commercialized products that its licensees market, and it is the exclusive manufacturer of those products. | Product or program | What it is | Stage | |---|---|---| | Anaphylm (dibutepinephrine) sublingual film | Oral epinephrine prodrug film for severe allergic reactions including anaphylaxis | CRL received January 30, 2026; NDA resubmission planned | | AQST-108 (epinephrine) topical gel | Epinephrine prodrug candidate from the AdrenaVerse platform | | | PharmFilm | Oral film drug delivery technology | | Summarised from the company's [10-K filed Mar 4, 2026](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm). ## Aquestive Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$17.2 million](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/) | [$20.3 million](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/) | | Net income (loss) | [-$83.8 million](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/) | [-$44.1 million](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/) | | Cash from operations | [-$52.4 million](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/) | [-$35.8 million](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/) | | Cash and equivalents | [$121.2 million](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000042/) | [$71.5 million](https://www.sec.gov/Archives/edgar/data/1398733/000139873325000028/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $98.5 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Aquestive Therapeutics Is there a class action against Aquestive Therapeutics? Our latest story on this, dated Sep 17, 2026: "Aquestive faces securities class action and derivative suit over Anaphylm NDA statements". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/aquestive-faces-securities-class-action-derivative-suit-anaphylm-nda/). Has Aquestive Therapeutics raised money recently? Our latest story on this, dated Aug 14, 2025: "Aquestive Therapeutics prices $85,000,000 stock offering at $4.00 per share". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/aquestive-therapeutics-prices-85-000-000-stock-offering-4-00-share/). What is the ticker symbol of Aquestive Therapeutics? Aquestive Therapeutics, Inc. trades under the ticker AQST on NASDAQ. Where is Aquestive Therapeutics listed? Aquestive Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Aquestive Therapeutics? The SEC Central Index Key (CIK) for Aquestive Therapeutics, Inc. is 1398733. Its filings are on SEC EDGAR. How many shares does Aquestive Therapeutics have outstanding? 125,511,648 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is Aquestive Therapeutics listed under? Our directory records Aquestive Therapeutics, Inc. under United States. What does Aquestive Therapeutics do? Our directory classifies Aquestive Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Aquestive Therapeutics? The ISIN recorded for Aquestive Therapeutics, Inc. is US03843E1047. Does aibio.space cover Aquestive Therapeutics? aibio.space lists Aquestive Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Aquestive Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Aquestive Therapeutics develop? Aquestive Therapeutics is a pharmaceutical company developing medicines that deliver complex molecules through alternatives to invasive and inconvenient standard of care therapies. Its late-stage product candidate, Anaphylm (dibutepinephrine), is a sublingual film for severe allergic reactions, including anaphylaxis, which the company describes as the first and only non-device based, orally delivered epinephrine prodrug in development. What is Anaphylm (dibutepinephrine) sublingual film from Aquestive Therapeutics? Anaphylm (dibutepinephrine) sublingual film: Oral epinephrine prodrug film for severe allergic reactions including anaphylaxis Stage: CRL received January 30, 2026; NDA resubmission planned. What is AQST-108 (epinephrine) topical gel from Aquestive Therapeutics? AQST-108 (epinephrine) topical gel: Epinephrine prodrug candidate from the AdrenaVerse platform Is Aquestive Therapeutics profitable? Aquestive Therapeutics, Inc. reported a net loss of $83.8 million for the fiscal year ended Dec 31, 2025, and used $52.4 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Aquestive Therapeutics Members talk about Aquestive Therapeutics (AQST). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Aquestive Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-06-26 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1398733/000114036126026568/ny20076831x1_s3.htm) 2. 2026-05-13 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,1.02,2.02,2.03,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000029/q12026-ex991earningsrelease.htm) 3. 2026-05-13 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000030/aqst-20260331.htm) 4. 2025-08-14 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1398733/000114036125031320/ny20053995x1_424b5.htm) 5. 2024-11-04 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1398733/000162828024045030/aqst-20240930.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:AQST on TradingView](https://www.tradingview.com/symbols/NASDAQ-AQST/). ## SEC filings and registration - **SEC name**: Aquestive Therapeutics, Inc. - **CIK**: 1398733 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: AQST (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 184 LIBERTY CORNER ROAD, WARREN, NJ - **Phone**: 908-941-1900 - **Shares outstanding**: 125,511,648 as of 2026-08-07 (10-Q filed 2026-08-11) - **Former names**: MonoSol Rx, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000063/aqst-20261015.htm) filed 2026-10-19 - [8-K](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000058/aqst-20261015.htm) filed 2026-10-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000056/aqst-20261013.htm) filed 2026-10-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000052/aqst-20260929.htm) filed 2026-09-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000048/aqst-20260923.htm) filed 2026-09-25 - [8-K](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000044/aqst-20260914.htm) filed 2026-09-17 - [10-Q](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000042/aqst-20260630.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000041/aqst-20260811.htm) filed 2026-08-11 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001398733), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Aquestive Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker AQST, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Aquestive Therapeutics, Inc. - **Ticker**: AQST - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US03843E1047 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-AQST/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/aquestive-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Aquestive Therapeutics (AQST) news: class action and offering", 2026-10-31, https://aibio.space/companies/aquestive-therapeutics/